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The Drori (Dra) antigen is one of the ten high-prevalence antigens
of the Cromer blood system, which are carried on decay-
accelerating factor (DAF, CD55). The Dr(a–) phenotype was first
described in a 48-year-old Jewish woman from Bukhara. Her serum
contained an antibody to a high-prevalence antigen named anti-Dra.
Most known individuals with the Dr(a–) phenotype are Jews from
the geographic area of Bukhara, but individuals from Japan have
also been described. Antibodies in the Cromer blood group system,
including anti-Dra,have never been reported to cause HDN. In most
of the cases with anti-Dra examined in Israel, the antibodies have
been subtyped as IgG2 and IgG4. This report is of a woman with
Dr(a–) phenotype and an anti-Dra titer of 256 to 512 in her serum,
observed during two successive pregnancies. At birth, the RBCs of
the first- and second-born child were negative and positive in the
DAT, respectively, and neither manifested clinical signs of HDN. The
disappearance of Cromer system antibodies, including anti-Dra in
midpregnancy, has been described in a previous study. In that
study, it was theorized that the antibodies in the serum of the
women were adsorbed onto placental DAF. The finding of a high
anti-Dra titer in two successive pregnancies in this patient, with a
positive DAT for the RBCs of one of the two babies at term, differs
from published reports, suggesting that a different mechanism
might be involved. Immunohematology 2005;21:126–128.
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The Drori (Dra) antigen is part of the Cromer blood
group system, which includes ten high- and three low-
prevalence antigens.1 The Cromer antigens are carried
on the complement regulatory glycoprotein decay-
accelerating factor (DAF;CD55). The Dr(a–) phenotype
was first described in a 48-year-old Jewish woman of
Bukharian origin by Levene et al.2 More cases have
been published; most of them were of Jewish women
born in Bukhara, a few were of individuals from
Japan.3,4
Antibodies in the Cromer system have not been
reported to cause clinical HDN.1 There are reports in
the literature of women with Cromer antibodies in
which the titer fell during pregnancy and the baby
carrying a Cromer antigen was born with a negative
DAT.5,6 DAF is expressed strongly on the apical surface
of trophoblasts, more so in the second and third
trimesters.7 The placental trophoblasts possess the
DAF polymorphism of the fetus, which is inherited
from both parents and is most likely positive for the
high-prevalence Cromer antigens, including Dra. Reid
et al.8 suggested that antigen-positive trophoblasts may
absorb maternal antibodies with DAF specificity such
as anti-Dra, causing their disappearance from maternal
blood and explaining the lack of HDN secondary to this
antibody. They reported two cases with Cromer
antibodies, one of them anti-Dra, which disappeared
during pregnancy, supporting their hypothesis.
In this report two successive pregnancies in a
Dr(a–) woman with anti-Dra in her serum are described.
The anti-Dra titers did not change significantly
throughout either pregnancy. At birth,a DAT performed
on the RBCs of the first baby was negative and that
performed on those of the second baby was positive.
Neither baby had clinical evidence of HDN.
Case Report
A 28-year-old Jewish woman of Bukharian origin in
her second pregnancy was admitted to the Assaf
Harofeh Medical Center delivery room in labor in
March 1998. A RBC sample was sent to the blood bank
for blood type and antibody screen. An antibody to a
high-prevalence antigen was found in her serum and
investigated. Her RBCs were typed as Group A1,D–,C–,
E–, c+, e+, Cw–; M–, N+, S–, s+; P1–; Lu(a–b+); K–, k+,
Kp(a–b+); Le(a–b+); Jk(a+b+); Yt(a+), and Dr(a–) and
the DAT was negative. During testing for the Cromer
antigens,weaker reactions were observed with anti-IFC
and -Cra when compared with the positive controls. A
sample from her husband was tested and his RBCs
were determined to be Group A1, D+, C+, E–, c–, e+,
Cw–; M+, N+, S–, s+; P1+; Lu(a–b+); K–, k+, Kp(a–b+);
Fy(a+b+); Jk(a+b–);Yt(a+b–),and Dr(a+). His antibody
screen and DAT were negative.
The patient was found to have anti-D (low titer
from passive immunization in pregnancy) and anti-LebH.
An antibody to a high-prevalence antigen was found in
her serum,which was characterized as anti-Dra, and her
RBCs typed as Dr(a–). The titer of the antibody by
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saline indirect antiglobulin test was 512 (Table 1). The
patient’s serum was examined with two known Dr(a–)
RBCs and the presence of anti-K, anti-M, anti-S, and anti-
P1 were excluded.
Materials and Methods
Standard tube hemagglutination tests were used for
antigen typing, antibody screening, and panels.
Antibodies and rare RBCs used in the testing were from
the Israeli National Blood Group Reference Laboratory
and SCARF. Column agglutination tests (DiaMed AG,
Switzerland) were also used for antibody screening and
panels. The RBCs were examined with anti-DAF
(CD55) and anti-MIRL (CD59) in column agglutination
tests (DiaMed AG). The elution was performed using
the rapid acid method (Elukit II, Gamma Biologicals,
Inc., Houston,TX).
Results
The RBCs of the newborn were negative in the
DAT and there was no clinical evidence of HDN. In
May 2000, during her next pregnancy, anti-Dra was
identified with a titer of 256 (Table 1). In June 2000,
the anti-Dra titer was 512 and in July 2000 the titer was
256. The pregnancy was uncomplicated and RhIG was
again administered antenatally. The patient gave birth
in October 2000 to a full-term healthy baby, the titer
remaining stable throughout pregnancy. The infant’s
RBCs were typed as Group A, D+; the DAT was positive
with anti-IgG resulting in 2+ to 3+ reactivity in tubes
and 4+ by the column agglutination test (DiaMed AG).
The positive DAT precluded Dra typing. An elution was
performed on the baby’s RBCs and anti-Dra was
identified. The eluate did not react with RBCs from the
mother, Dr(a–) RBCs, or RBCs treated with alpha-
chymotrypsin. There was no clinical evidence of HDN.
The titer of the anti-Dra in the mother’s serum was 256.
Testing of maternal RBCs by the column agglutination
test (DiaMed) was negative with anti-DAF (CD55) and
positive with anti-MIRL (CD59).
Discussion
DAF is a protein connected to the membrane via a
glycosylphosphatidylinositol anchor. It protects cells
against destruction by autologous complement by
inhibiting formation and acceleration of the decay of
C3 and C5 convertases, thus preventing the
complement cascade from causing hemolysis. DAF is a
member of the regulators of complement activation
gene family encoded by a gene on the long arm of
chromosome 1.9 It is widely distributed throughout
the body and expressed on epithelial cells, endothelial
cells, blood vessels, and the apical surface of
trophoblasts.7,10 The Cromer antigens are carried on
DAF and the different phenotypes provide a basis for
biochemical and functional investigation of alternate
forms of DAF. Dr(a–) is a rare Cromer phenotype,
lacking expression of the Dra antigen, with reduced
levels of DAF and weak expression of other Cromer
antigens, including Cra, Tca, Tcb, Tcc, Esa, IFC, Wesb, and
UMC.10 No hematological abnormalities have been
described in Dr(a–) individuals. The molecular change
associated with Dr(a–) has been characterized.9 Four
pregnancies in a woman who had Cr(a–) RBCs and
anti-Cra, in which the titer of the anti-Cra declined
during pregnancy and remained low until term, were
described by Sacks and Garratty.6 The decline in the
titer was thought to result from absorption of the
antibody by white cells or platelets or be due to
neutralization by plasma of the fetus. Another case of
anti-Cra in a pregnant woman in which the titer of the
anti-Cra decreased was described by Dickson et al.5
Reid et al.8 described two patients with repeat
pregnancies who had Cromer blood group system
antibodies (anti-Cra and anti-Dra) with titers of 128 or
greater at the beginning of pregnancy. These
antibodies became undetectable in the serum from the
second trimester onward. RBCs from the babies tested
positive for the relevant Cromer antigens but were
negative by the DAT. The antibodies would reappear in
the serum of the mother after delivery or at the
beginning of a subsequent pregnancy.
Holmes et al.7 showed the preferential expression
of DAF at the feto-maternal interface of the placenta,
increasing quantitatively during placental develop-
ment. DAF at this site plays a protective role against
maternal complement-mediated attack. DAF can
absorb the Cromer antibodies produced by the mother,
more so in the second and third trimesters when the
expression of DAF increases. This hypothesis is
supported by reappearance of these antibodies after
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pregnancy when the placenta is no longer present.
Most of the patients with anti-Dra found in Israel have
been multiparous women. Subclasses of IgG examined
in these cases during the years 1989–1991 were IgG2
and IgG4. The anti-IgG subtype antibodies used were
from the Netherlands Red Cross and tests were
performed in tube or capillary tests. None of the
offspring had HDN (C. Levene, unpublished data,
1989–1991). The patient reported here was Dr(a–).
She developed anti-Dra and was monitored during two
subsequent pregnancies. The anti-Dra titer remained
consistently at 256 or above during both pregnancies.
RBCs from the first baby typed as Dr(a+) and the DAT
was negative.RBCs from the second baby were positive
in the DAT; they could not be typed for the Dra antigen,
but anti-Dra was identified in the eluate,with no clinical
signs of HDN. Our findings differ from previous5,6,8,11
reports, where anti-Cromer antibody titer declined
during pregnancy. Reid et al.8 suggested that the titer
decreased due to Cromer blood group system
antibodies binding to the placental DAF. In the case
described here, presumably the anti-Dra was not
adsorbed by the placental DAF, which might happen if
the placental DAF was Dr(a–), if Dra was poorly
expressed, or due to another unexplained mechanism.
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